To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.

Double-blinded, Randomized, Active Control, Single Center-designed, Phase I Clinical Trial to Evaluate the Safety and Efficacy for Improvement of Glabellar Lines of "HG-102" Compared to Botox® in Subjects With Moderate to Severe Glabellar Lines

To compare the safety and efficacy of "HG-102" with Botox® in the improvement of moderate to severe glabellar lines.

Double-blinded, Randomized, Active control, Single center-designed, Phase I clinical trial to evaluate the safety and efficacy for improvement of Glabellar Lines of "HG-102" compared to Botox® in subjects with moderate to severe Glabellar Lines

Inclusion Criteria:

• Men and women aged between 19 and 65 at screening visit.
• Patients who voluntarily sign the informed consent.
• Patients who can comply with the study procedures and visit schedule.

Exclusion Criteria:

• Patients with infection, skin disorders, or scars at the glabellar region.
• Patients with facial palsy or the symptoms of blepharoptosis.
• Fertile women and men who have plans to conceive during pregnancy, breastfeeding and clinical trials or who do not agree to appropriate contraception.
• Subjects who are not eligible for this study based on investigator's judgement.